However other clinical trials combining a TKI with an ICI failed to demonstrate efficacy over standard-of-care in MSS CRC patients, including lenvatinib plus pembrolizumab in LEAP-017 [46], and cobimetinib (a MEK inhibitor) plus atezolizumab in the Imblaze370 phase III trial [47]. This evidence concerns the gene MAP2K7 and colorectal carcinoma.